Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.35 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.35 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.35 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6770232 | 0.78 | — | — | |
| Bromide SCHEMBL8481327 | 0.75 | ACHE (0.43) | CA1CA2CA7CA9ACHE | |
| Bromide SCHEMBL2341787 | 0.75 | CA1 (0.36) | CA1CA2CA7CA9ACHE | |
| SCHEMBL137718 | 0.71 | — | — | |
| SCHEMBL2869266 | 0.71 | — | — | |
| Bromide SCHEMBL4241918 | 0.71 | LMNA (0.50) | CA1CA2IDO1CES2CES1 | |
| Bromide SCHEMBL23467127 | 0.69 | ACHE (0.38) | CA1CA2CA7CA9ACHE | |
| Bromide SCHEMBL11150430 | 0.69 | ACHE (0.38) | CA1CA2CA7CA9ACHE | |
| Water SCHEMBL456925 | 0.69 | CA1 (0.36) | CA1CA2CA7CA9ACHE | |
| Hydrochloric Acid SCHEMBL5318657 | 0.69 | CA1 (0.36) | CA1CA2CA7CA9ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1810969-B1 | ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | MSD KK (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-7932394-B2 | 1-{[5-[4-(Methylsulfonyl)phenoxy]-2-(2-pyridinyl)-1H-benzimidazol-6-yl]methyl}-5-thioxo-2-pyrrolidinone;glucokinase activator; antidiabetic agents; obesity; prevention of retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis; antiischemic agents; cardiotonic agents | MSD K.K. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20080125429-A1 | Aryloxy-Substituted Benzimidazole Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| EP-1810969-A1 | ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125429-A1 | Aryloxy-Substituted Benzimidazole Derivatives | GCK, GCKR, SLC5A1 | ACHE 1722/4885CA1 3114/4885CA2 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.